MCE has established a comprehensive compound library and quality control system, with over 50000 high-purity bioactive compounds, including numerous innovative molecules developed exclusively. The company's mission is to accelerate drug research and development, providing comprehensive solutions from early-stage compounds to preclinical candidates, including compound screening, target validation, and pharmacological evaluation services. MCE maintains close cooperation with top global research institutions and biopharmaceutical companies, and its products are widely used in major disease research fields such as cancer, neurodegenerative diseases, metabolic diseases, etc.

In 2023, MCE will continue to maintain rapid growth, with annual sales exceeding $300 million and steadily increasing market share in the United States and Europe. The company has recently expanded its research and development center and GMP production base, and launched an AI assisted drug design platform. In the next three years, MCE plans to expand its compound library to 80000 species and strengthen its layout in emerging technologies such as PROTAC and molecular gels, committed to becoming the most trusted partner and solution provider in the global drug research and development field.